Dexlevo's liquid-form PCL collagen stimulator GOURI, already shipped to 50 countries, officially launched in Korea five years after global debut. The May 19 symposium in Seoul showcased preclinical data, clinical trials, and real-world techniques, signaling a new option for overseas buyers seeking differentiated biostimulators with a nodule-free profile.
Market signal
GOURI's Korean launch marks a strategic entry into a competitive biostimulator market. With MFDS approval secured in September 2025, the product now targets domestic and international distributors. Its liquid-form PCL, free of microspheres, aims to address common concerns like nodules and granulomas, potentially appealing to clinics seeking safer collagen stimulators.
Preclinical and clinical evidence
Prof. Beomjoon Kim presented data from a 218-patient trial published in JCD, showing a 70.23% crow's feet improvement at 12 weeks vs. 61.40% for a PN filler. No severe adverse events were reported. He explained that the liquid form avoids frustrated phagocytosis and biofilm formation, though he cautioned that nodules remain theoretically possible with any filler.
Technique and delivery insights
Dr. Jeyoung Park compared needle-free injectors, multi-needle devices, and cannulas. Needle-free injection at 0.3–0.5 mm depth improved skin texture, while cannula injection at 2.5 mm or deeper favored tightening and volumization. Dr. Jimyung Seo, with 800+ vials of experience, noted a two-vial session takes about nine minutes using a 25G cannula, and treatment areas extend to hands, neck, and knees.
What buyers should watch
Overseas distributors should monitor GOURI's nodule-free claims and fast procedure time as competitive advantages. The product's five-year global track record across 50 countries provides real-world safety data. However, the absence of severe adverse events in trials does not guarantee zero risk, so due diligence on training and patient selection is advised.
Sourcing context
Dexlevo, a Korean manufacturer, now offers GOURI for domestic and international distribution. The product's liquid PCL formulation differentiates it from microsphere-based competitors. Buyers should evaluate regulatory approvals in their markets and consider the need for specialized injection training, as technique depth influences outcomes.
Source: Read the original report | Published: May 31, 2026